Potential clinical actionability.

Slides:

Advertisements

Similar presentations

Progress Against Pancreatic Cancer. 1970–1979 Progress Against Pancreatic Cancer 1970– s: Tobacco use found to cause pancreatic cancer.

Advertisements

Yan Guo Assistant Professor Department of Cancer Biology Vanderbilt University USA.

PIK3CA gene amplification in glioblastoma and squamous cell carcinoma (SCC) of the lung. PIK3CA gene amplification in glioblastoma and squamous cell carcinoma.

Precision Medicine: The Potential for Identifying Personalized Therapies for Patients with Gastro-Esophageal Cancer.

AACR Project GENIE: The Role of Patients and Patient Advocates in

Dose-escalation patient response.

Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers Melinda Mata, Stephen.

Clinical trial matching.

A B Tumour 74 – Whole Genome Tumour 74 – Whole Genome C D

Landscape overview of GENIE dataset.

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

PARPi combinations against HR-proficient tumors.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

A, baseline and 4-week PET scan from patient 2 (MET c

CSCI2950-C Lecture 3 September 13, 2007.

Genomic alterations in breast cancer cell line MDA-MB-231.

Genomic alterations in non–small cell lung cancer, breast cancer, and colorectal cancer. Genomic alterations in non–small cell lung cancer, breast cancer,

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Intrinsic and acquired trastuzumab resistance.

Copy-number alterations in an archival breast cancer sample.

Суури мэдлэг Basic Knowledge

AACR Project GENIE at a glance.

Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

The Genetic Basis for Cancer Treatment Decisions

Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.

PD-1 expression on HCC-infiltrating B cells and its clinical significance. PD-1 expression on HCC-infiltrating B cells and its clinical significance. A–H,

Mapping Cancer Origins

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

C.2.10 Sample Questions.

C.2.8 Sample Questions.

C.2.8 Sample Questions.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

To Infinium, and Beyond! Cancer Cell

Effect of HA on hematopoietic recovery in tumor-bearing mice.

A and B, Computed tomography (CT) of the chest prior to cabozantinib therapy demonstrated a dominant mass in the left upper lobe (B, black arrow), measuring.

Frequent alterations identified and potential actionability.

Response of the Idh2R140Q Flt3ITD leukemia model to AG-221 therapy.

Overexpression of JMJD2B in clinical bladder cancers.

Effect of naïve or SCM percentage and cytokines on expansion potential

KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Personalized genomic analyses for cancer mutation discovery and interpretation by Siân Jones, Valsamo Anagnostou, Karli Lytle, Sonya Parpart-Li, Monica.

HGSOC mutational processes are established early and are patient-specific. HGSOC mutational processes are established early and are patient-specific. A,

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Selected overview of clinical trials evaluating FGFR signaling–targeted therapies currently under development (monotherapy). Selected overview of clinical.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Individual treatment outcomes of 20 patients treated with afatinib and 12 patients treated with afatinib and trastuzumab. Individual treatment outcomes.

Representative patient responses to ulixertinib.

Ten most frequent TCRs in the bulk 12TILs comprise >99% of the TIL population, and the neoantigens are shown to be the most dominant clones. Ten most frequent.

Frequently mutated genes in colorectal cancer.

A, VEGFR2 staining in the tumor rim and center.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

A and B, linearity of the preamplification step shown by a similar expression pattern of ERα mRNA in four breast tumor samples pre– and post–linear amplification.

Strategies for personalized precision immunotherapy.

Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.

Enrichment of two rare SNPs among ABC DLBCL tumors.

JAK3 mutations and ectopic expression of HOXA9 are significantly associated in clinical T-ALL cases. JAK3 mutations and ectopic expression of HOXA9 are.

Germline variants influencing primary tumor type.

One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine.

STK11/LKB1 mutations are a genomic determinant of poor clinical outcome with PD-1 axis blockade in PD-L1–positive nonsquamous NSCLC, regardless of KRAS.

A variety of ROS1 gene fusions occur across multiple tumor types.

High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.

Driver pathways and key genes in OSCC

CASP8 mutations are associated with fewer CNAs and RAS family mutations. CASP8 mutations are associated with fewer CNAs and RAS family mutations. A, number.

Integrated analysis of gene expression and copy number alterations.

Highly metastatic PDAC cells have a unique gene signature, which is not preserved in metastases but predicts poor patient outcome. Highly metastatic PDAC.

Molecular characterization of esophagogastric tumors.

Mitochondrial DNA as a Cancer Biomarker

Presentation transcript:

Potential clinical actionability. Potential clinical actionability. Tumor types are shown by decreasing overall frequency of actionability. Actionability was defined by the union of three knowledge bases: My Cancer Genome (http://mycancergenome.org), OncoKB (http://oncokb.org), and the Personalized Cancer Therapy knowledge base (http://pct.mdanderson.org). For each tumor sample, the highest level of actionability of any variant was considered. Only tumor types with 100 or more samples were included in this analysis. The AACR Project GENIE Consortium Cancer Discov 2017;7:818-831 ©2017 by American Association for Cancer Research